Chau Q. Khuong is Partner in the Private Equity group at OrbiMed Advisors, a global healthcare-dedicated investment firm with approximately $15 billion in assets under management. During his career, Mr. Khuong has been an active lead investor in innovative drug development and medical device enterprises across all stages and numerous therapeutic areas including oncology, infectious diseases, ophthalmology, gene editing, and the microbiome. He currently serves as a Board director of several public and private companies, including Aerpio Therapeutics, Inc., Cerapedics, Inspire Medical Systems, Intellia, Nabriva (NASDAQ: NBVR), NextCure, Otonomy, Inc. (NASDAQ: OTIC), Pieris Pharmaceuticals (NASDAQ: PIRS), ReViral Ltd, and Synlogic. He holds a B.S. in molecular, cellular and developmental biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.